alpha-aminopyridine has been researched along with Blood Clot in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Aarts, MJB; Eble, JA; Fernandez, DI; Heemskerk, JWM; Kuijpers, MJE; Tullemans, BME; van der Meijden, PEJ; Veninga, A | 1 |
| Al-Samkari, H; Shatzel, JJ; Wander, SA; Watson, NW | 1 |
| Alenazy, FO; Harbi, MH; Nicolson, PLR; Smith, CW; Thomas, MR; Tiwari, A; Watson, SP | 1 |
| Fu, J; Herzog, B; Hess, PR; Jakus, Z; Kahn, ML; Lu, M; Makinen, T; Nieswandt, B; Oliver, G; Rawnsley, DR; Sweet, DT; Xia, L; Yang, Y | 1 |
| Gupta, N; Li, W; McIntyre, TM | 1 |
| Amore, C; Beume, R; Dell'Elba, G; Di Santo, A; Evangelista, V; Martelli, N; Piccoli, A; Tenor, H; Totani, L | 1 |
| Bryant, JW; Gibson, GW; Kolte, D; Shariat-Madar, Z; Wang, J | 1 |
| Berry, CN; Ferrari, P; Herbert, JM; Lechaire, I; Lochot, S; Lorrain, J; Lunven, C; Millet, L; O'Connor, SE; Sainte-Marie, M; Schaeffer, P; Visconte, C | 1 |
| Altenburger, JM; Berry, CN; Bocskei, Z; Galtier, D; Herault, JP; Herbert, JM; Jetha, JC; Lassalle, GY; Lorrain, J; Lunven, C; Matrougui, M; O'Connor, SE; Schaeffer, P | 1 |
| Herbert, JM; Lorrain, J; Millet, L; O'Connor, SE; Sainte-Marie, M; Schaeffer, P; Visconte, C | 1 |
| Chen, IW; Coburn, CA; Di Muzio-Mower, JM; Homnick, C; Juliano, M; Krueger, JA; Lewis, SD; Lucas, BJ; Lyle, EA; Rush, DM; Vacca, JP; Vastag, K; Williams, PD | 1 |
11 other study(ies) available for alpha-aminopyridine and Blood Clot
| Article | Year |
|---|---|
Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment.
Topics: Aminopyridines; Antineoplastic Agents; Blood Platelets; Calcium Signaling; Collagen; Dasatinib; Dose-Response Relationship, Drug; Drug Repositioning; Humans; Morpholines; Phthalazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Thrombosis | 2021 |
Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer.
Topics: Aminopyridines; Anticoagulants; Benzimidazoles; Breast Neoplasms; Female; Humans; Thrombosis; Venous Thromboembolism | 2022 |
Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs.
Topics: Aminopyridines; Animals; Aspirin; Fibrinolytic Agents; Humans; Mice; Morpholines; Oxazines; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Pyridines; Pyrimidines; Thrombosis; Ticagrelor | 2022 |
Platelets mediate lymphovenous hemostasis to maintain blood-lymphatic separation throughout life.
Topics: Aminopyridines; Animals; Blood Platelets; Fibrin; Hemostasis; Intestines; Intracellular Signaling Peptides and Proteins; Lectins, C-Type; Lymph Nodes; Lymphatic Vessels; Mice; Mice, Knockout; Morpholines; Oxazines; Platelet Aggregation; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Regional Blood Flow; Syk Kinase; Thoracic Duct; Thrombosis; Venous Valves | 2014 |
Deubiquitinases Modulate Platelet Proteome Ubiquitination, Aggregation, and Thrombosis.
Topics: Aminopyridines; Animals; Benzoates; Blood Platelets; Chlorides; Disease Models, Animal; Enzyme Inhibitors; Ferric Compounds; Furans; Humans; Mice, Inbred C57BL; Microfluidic Analytical Techniques; Microscopy, Interference; Piperidones; Platelet Aggregation; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Proteasome Endopeptidase Complex; Pyrazoles; Receptors, Collagen; Receptors, Thrombin; Signal Transduction; Thiocyanates; Thrombosis; Ubiquitin Thiolesterase; Ubiquitin-Specific Proteases; Ubiquitination | 2015 |
Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Topics: Aminopyridines; Animals; Benzamides; Blood Platelets; Cardiovascular Diseases; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Extracellular Traps; Fibrinogen; Humans; Leukocytes; Macrophage-1 Antigen; Mice; Microscopy, Confocal; Monocytes; Neutrophils; P-Selectin; Phosphatidylinositol 3-Kinases; Phosphodiesterase 4 Inhibitors; Phosphorylation; Platelet Adhesiveness; Pulmonary Disease, Chronic Obstructive; Risk; Thromboplastin; Thrombosis | 2016 |
PF-04886847 (an inhibitor of plasma kallikrein) attenuates inflammatory mediators and activation of blood coagulation in rat model of lipopolysaccharide (LPS)-induced sepsis.
Topics: Aminobenzoates; Aminopyridines; Animals; Blood Coagulation; Disease Models, Animal; Disseminated Intravascular Coagulation; Dose-Response Relationship, Drug; Inflammation Mediators; Lipopolysaccharides; Male; Plasma Kallikrein; Rabbits; Rats; Rats, Sprague-Dawley; Respiratory Distress Syndrome; Sepsis; Thrombosis | 2012 |
Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor.
Topics: Administration, Oral; Aminopyridines; Animals; Bleeding Time; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Male; Rabbits; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombin; Thrombosis | 2003 |
SSR182289A, a selective and potent orally active thrombin inhibitor.
Topics: Administration, Oral; Aminopyridines; Animals; Azetidines; Benzylamines; Blood Coagulation; Crystallography, X-Ray; Disease Models, Animal; Humans; Hydrogen Bonding; Male; Models, Molecular; Molecular Structure; Platelet Aggregation; Rats; Structure-Activity Relationship; Sulfonamides; Thrombin; Thrombosis | 2004 |
SSR182289A enhances thrombolysis induced by fibrinolytic agents in rabbit models of venous and arterial thrombosis.
Topics: Aminopyridines; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Femoral Artery; Fibrinolytic Agents; Jugular Veins; Male; Rabbits; Streptokinase; Sulfonamides; Thrombolytic Therapy; Thrombosis; Tissue Plasminogen Activator | 2004 |
Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors.
Topics: Acetamides; Aminopyridines; Animals; Anticoagulants; Biological Availability; Dipeptides; Dogs; Drug Design; Drug Evaluation, Preclinical; Humans; Molecular Mimicry; Pyridones; Rats; Structure-Activity Relationship; Thrombin; Thrombosis | 2000 |